The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme

Towards Tailored Therapy of Glioblastoma Multiforme

(2014) N.H. Rekers et al.   JOURNAL OF CHEMOTHERAPY

An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth

(2012) Fadila Guessous et al.   Anti-Cancer Agents in Medicinal Chemistry

Progress in cancer therapy targeting c-Met signaling pathway

(2012) Kyung Hee Jung et al.   ARCHIVES OF PHARMACAL RESEARCH

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

HGF/c-MET Targeted Therapeutics: Novel Strategies for Cancer Medicine

(2011) Timothy A. Yap et al.   CURRENT DRUG TARGETS

Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies

(2011) K. Masui et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

(2011) Q. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

 -Secretase Inhibitors Enhance Temozolomide Treatment of Human Gliomas by Inhibiting Neurosphere Repopulation and Xenograft Recurrence

(2010) C. A. Gilbert et al.   CANCER RESEARCH

C-MET as a new therapeutic target for the development of novel anticancer drugs

(2010) Israel Cañadas et al.   Clinical & Translational Oncology

Survival comparison between glioblastoma multiforme and other incurable cancers

(2010) B. Tran et al.   JOURNAL OF CLINICAL NEUROSCIENCE

c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme

(2010) Wei Liu et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas

(2010) X.-Z. Hou et al.   NEURO-ONCOLOGY

Glioblastoma multiforme: a review of therapeutic targets

(2009) Okezie O Kanu et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

(2009) S. G. Buchanan et al.   MOLECULAR CANCER THERAPEUTICS

The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells

(2009) James W Welsh et al.   Radiation Oncology

Prognostic significance of c-Met expression in glioblastomas

(2008) Doo-Sik Kong et al.   CANCER